key: cord-0894130-ke59898e
authors: Sallustio, F.; Curci, C.; Cimmarusti, M. T.; Picerno, A.; De Palma, G.; Sivo, C.; Annese, F.; Fonto, G.; Stasi, A.; Pesce, F.; Di Leo, V.; Gesualdo, L.
title: Elevated Levels of IL-6 in IgA Nephropathy patients are induced by an Epigenetically-Driven Mechanism Triggered by Viral and Bacterial RNA
date: 2022-03-07
journal: nan
DOI: 10.1101/2022.03.05.22271944
sha: a10fe72be03b812c11bfa717e47caa87626fd1d1
doc_id: 894130
cord_uid: ke59898e

Recently, a several models has been proposed to describe the pathogenesis of Immunoglobulin A nephropathy (IgAN), and among them the multihit and the gut-microbiota. These models explain the pathogenesis of IgAN caused by the production of aberrant IgA, but it is believed further predisposing factors are present, including immunological, genetic, environmental, or nutritional factors that can influence the pathogenesis and that could be useful for development of precision nephrology and personalized therapy. Newly, the role of IL-6 in pathogenesis is becoming increasingly important. It is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice, even if the reason why levels of IL-6 are elevated in IgAN patients is not well understood. One attainable hypothesis on high levels of IL-6 in IgAN comes out from our recent whole genome DNA methylation screening in IgAN patients, that identified, among others, a hypermethylated region comprising Vault RNA 2-1 (VTRNA2-1), a non-coding RNA also known as precursor of miR-886 (pre-mi-RNA). Consistently, the VTRNA2-1 expression was found down-regulated in IgAN patients. Here we confirm that VTRNA2-1 is low expressed in IgAN subjects compared to HS and we found that also in transplanted IgAN patients (TP-IgAN), compared to non IgAN transplanted patients (TP), the VTRNA2-1 transcript was expressed at level very low. We found that in IgAN patients with downregulated VTRNA2-1, PKR is overactivated, coherently with the role of the VTRNA2-1 that binds to PKR and inhibits its phosphorylation. The loss of the VTRNA2-1 natural restrain causes, in turn, the activation of CREB by PKR. We found CREB, a classical cAMP-inducible CRE-binding factor interacting with a region of the IL-6 promoter and leading to IL-6 production, overactivated both in IgAN and in TP-IgAN patients. Effectively, in the same patients, we found elevated levels of IL-6 correlating with CREB and PKR phosphorylation. Since PKR is normally activated by bacterial and viral RNA we hypothesized that these microrganisms can further activate the PKR/CREB/IL-6 pathway leading to an excess of IL-6 production, explaining both the high levels of IL-6, both infection involvement in the disease, both cases of IgAN associated with COVID-19 infection and with COVID-19 RNA-vaccination, and recent data showing microbiota involvment in IgAN. Effectively, we found that Effectively, we sfound that both the RNA poly(I:C) and the COVID-19 RNA-vaccine stimulation significantly increase the IL-6 levels in IgAN patient PBMCs. The PKR/CREB/IL-6 pathway may be very important also in the setting of renal transplantation. We found that this pathway is upregulated also in IgAN transplanted patients. Recent studies showed that the cumulative risk of IgA nephropathy recurrence increases after transplant and is associated with a 3.7-fold greater risk of graft loss. Finally, we showed that the IL-6 secretion can be reduced by the PKR inhibitor imoxin. In conclusion, the discovery of the upregulated VTRNA2-1/PKR/CREB/IL-6 pathway in IgAN patients may provide novel approach to treat the disease and may be useful for development of precision nephrology and personalized therapy, possibly by checking the VTRNA2-1 methylation level in IgAN patients.

Since PKR is normally activated by bacterial and viral RNA we hypothesized that these 45 microrganisms can further activate the PKR/CREB/IL-6 pathway leading to an excess of IL-6 46 production, explaining both the high levels of IL-6, both infection involvement in the disease, both 47 cases of IgAN associated with COVID-19 infection and with and 48 recent data showing microbiota involvment in IgAN. 49 Effectively, we found that Effectively, we sfound that both the RNA poly(I:C) and the COVID-19 50 RNA-vaccine stimulation significantly increase the IL-6 levels in IgAN patient PBMCs. 51

The PKR/CREB/IL-6 pathway may be very important also in the setting of renal transplantation. 52

We found that this pathway is upregulated also in IgAN transplanted patients. Recent studies 53

showed that the cumulative risk of IgA nephropathy recurrence increases after transplant and is 54 associated with a 3.7-fold greater risk of graft loss. Finally, we showed that the IL-6 secretion can 55 be reduced by the PKR inhibitor imoxin. 56 57

In conclusion, the discovery of the upregulated VTRNA2-1/PKR/CREB/IL-6 pathway in IgAN 58 patients may provide novel approach to treat the disease and may be useful for development of 59 precision nephrology and personalized therapy, possibly by checking the VTRNA2-1 methylation 60 level in IgAN patients. 61 62 63 64 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

Immunoglobulin A nephropathy (IgAN), also known as Berger's disease, is the most frequent primary 66 glomerulonephritis characterized by the presence of IgA immune complexes in the glomeruli (1). It 67 generally appears in the second and third decade of life, has a higher incidence in males and it is more 68 common in whites than in blacks with a higher prevalence in Asians than Caucasians(1). 69

Recently, a multihit model has been proposed to describe the pathogenesis of IgAN. In this model, 70 the first hit is given by the hypersecretion of deglycosylated IgA (Gd-IgA1)(2). In circulation, these 71

Gd-IgA1 are recognized and attacked by autoantibodies (second hit) and this process leads to the 72 formation of circulating immune complexes (third hit), some of which are deposited at the mesangial 73 level in the glomeruli(2). Kidney damage resulting from the deposition of the cells is characterized 74 by local inflammation, complement activation, cell proliferation, and finally fibrosis (3). 75

Moreover, in humans, the gut-associated lymphoid tissue (GALT) is the primary source of IgA, so 76 the pathogenesis of IgAN is related to gut homeostasis. Indeed, the intestinal-renal axis is important 77 in Berger's glomerulonephritis, where several factors (e.g. genetics(4,5), infections(6,7), and food 78 antigens (8) may play a role in the disease complex pathogenesis and provide novel therapeutic targets 79 to modify disease evolution. 80 81 These models explain the pathogenesis of IgAN caused by the production of aberrant IgA, but it is 82 believed further predisposing factors are present, including immunological, genetic, environmental, 83 or nutritional factors that can influence the pathogenesis and that could be useful for development of 84 precision nephrology and personalized therapy. 85

We have recently showed that IgAN patients have a higher frequency of intestinal-activated B cells 86 than healthy subjects (HS). IgAN patients had greater BAFF cytokine blood levels, which were linked 87 to higher levels of five microbiota metabolites, and high APRIL cytokine serum levels. In comparison 88 to HS, IgAN individuals had a larger number of circulating gut-homing (CCR9 b7 integrin) regulatory 89 B cells, memory B cells, and IgA memory B cells(9). 90 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Moreover, several studies have shown the involvement of the IL-6 pathway in IgAN. Interleukin-6 is 91 essential for glomerular immunoglobulin A deposition and the development of renal pathology in 92 Cd37-deficient mice (10), Moreover, the proliferation-inducing ligand (APRIL) and IL-6 are 93 involved in the overproduction of aberrantly glycosylated IgA. In mice, the APRIL silencing blocked 94 the overproduction of Gd-IgA1 induced by IL-6 and, conversely, neutralizing IL-6, the production of 95

Gd-IgA1 was reduced(11). Interestingly, the mycotoxins deoxynivalenol (DON) prolonged exposure 96 cause the expansion of IgA secreting B cells by activating macrophages and T cells. In mice it results 97 in the early stages of human IgA nephropathy(12,13) and the overproduction of inflammatory 98 interleukins such as IL-6(14), which in turn induces upregulation of IgA. 99 100 However, to date, the biological mechanisms leading to the elevate IL6 levels in IgAN patients are 101 not clear. In a recent study, a whole-genome screening was performed for DNA methylation in CD4 + 102 T cells from IgAN patients, identifying three regions with altered methylation capable of influencing 103 the gene expression of genes involved in cell response and proliferation T CD4 + (15). In particular, a 104 hypermethylated region was identified comprising Vault RNA 2-1 (VTRNA2-1), a non-coding RNA 105 also known as the precursor of miR-886 (Pre-mi-RNA). 106

Here we studied the VTRNA2-1/PKR/CREB/IL-6 pathway showing that it is upregulated in IgAN 108 patients and that it is responsible for the elevated IL-6 levels characterizing the disease, thus providing 109 for the first time an explanation on the abnormal levels of this cytokine. We found that this pathway 110 is epigenetically controlled by VTRNA2-1 and triggered by bacterial and viral infections. It can 111 explain both the high levels of IL-6 both the correlation to mucosal infections of the disease. Finally, 112 we showed how the imoxin inhibitor, targeting this pathway, can reduce IL-6 secretion by PBMCs of 113 IgAN patients providing a new possible approach to treat the disease. 114 115 116 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Recently, we showed that the non-coding RNA VTRNA2-1 was epigenetically downregulated in 120

IgAN patients(15). Since we hypothesize that it may be implicated in the pathway for the secretion 121 of IL-6, we further confirm the involvement of VTRNA2-1 in IgAN studying its expression in 122

PBMCs isolated from IgAN patients and healthy subjects. 123 VTRNA2-1 was strongly downregulated in IgAN patients compared to healthy subjects showing a 124 decrease of 30 fold (p <0.05, Figure 1A ). Moreover, recent clinical observations have shown that IL-125 6 production is implicated in renal allograft rejection (16, 17) and that cumulative risk of IgA 126 nephropathy recurrence increased after transplant and was associated with a 3.7-fold greater risk of 127 graft loss (17). 128

We therefore analysed the expression of VTRNA2-1 in PBMCs isolated from IgAN patients with 129 kidney transplant (T-IgAN) and in patients non-IgAN with kidney transplant (TP). Also in this case, 130 we found that the VTRNA2-1 was extremely downregulated in transplanted IgAN patients compared 131 to their controls (p<0.0001, fold change=100; Figure 1B ), confirming that this modulation is a 132 characteristic of IgAN disease. 133 134 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. kinase, by binding to this protein and preventing its auto-phosphorylation(18). Thus, we studied 143 whether in the IgAN patients with low levels of VTRNA2-1 the correspective upregulation of the 144 PKR signalling was present. We measured the levels of the phosphorilated (pPKR) and of the total 145 PKR and found that in IgAN patients the level of pPKR protein normalized on the total PKR was 146 significantly increased compared to HS (FC 2.6; p<0.05; Fig. 2A ). At the same manner, also in T-147

IgAN we found the doubling of pPKR levels compared to TP (FC 2, p<0.05; Fig. 2B ). 148

To confirm that the incerase in pPKR levels was due to the auto-phosphorylation induced by the lack 149 of VTRNA2-1 and not by a different mechanism regulating the gene expression, we checked the PKR 150 mRNA levels in IgAN patients and in HS. We found no significant differences between the two group 151 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101/2022.03.05.22271944 doi: medRxiv preprint 8 ( Figure 2C ). However, in T-IgAN compared to TP we found rather a decrease of the PKR transcripts 152 ( Figure 

In mice pPKR induced the Cyclic adenosine monophosphate (AMP) response element-binding 163 protein (CREB) activation by increasing its phosphorilation (12). We studied whether in IgAN 164 patients CREB phosphorilation levels were higher compared to HS. A significant 3-fold increase of 165 pCREB levels was found in IgAN patients compared to HS (p<0.01; Fig. 3 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. Since several studies showed that CREB activation may lead to IL-6 expression(20-24), we analyzed 180 the IL-6 levels secreted by PBMCs in our IgAN patient groups. IL-6 levels showed a statistically 181 significant increase in IgAN patients compared to HS (p<0.05; Fig. 4A ). In T-IgAN compared to TP 182 a tendence in increased levels of IL-6 was found, even if it is not significant (Fig. 4B) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It selectively increases production of galactose-deficient IgA1 in IgA1-secreting cells from patients 231 with IgA nephropathy(29,30) and IL6-/-mice displayed no glomerular IgA deposition and were 232 protected from exacerbated renal failure following lipopolysaccharide treatment(32). Interestingly, 233 IL-6 signalling seems to be involved in this complex intestinal immune network particularly in 234 mediating the production of Gd-IgA(10,34). 235

One attainable hypothesis on high levels of IL-6 in IgAN comes out from our recent whole genome 236 DNA methylation screening in IgAN patients, that identified, among others, three regions with altered 237 DNA methylation capable of influencing the expression of genes involved in the response and 238 proliferation of T and B cells (15). We identified a hypermethylated region comprising Vault RNA 239 2-1 (VTRNA2-1), a non-coding RNA also known as precursor of miR-886 (pre-mi-RNA). 240

Consistently, the VTRNA2-1 expression was found down-regulated in IgAN patients(15). 241

Here we confirm that VTRNA2-1 is lower expressed in IgAN subjects compared to HS and we found 242 that also in transplanted IgAN patients compared to non IgAN transplanted patients the VTRNA2-1 243 transcript was expressed at level very low. The VTRNA2-1 gene produces an RNA polymerase III 244 transcript that resembles both a component of the ribonucleoprotein vault particle and a pre-245 microRNA. However, the RNA product does not function as a vault or microRNA; rather, it acts as 246 a direct inhibitor of protein kinase R (also known as eukaryotic translation initiation factor 2-alpha 247 kinase 2, EIF2AK2), and thereby plays an important role in the regulation of cell growth. This gene 248 is nearby a differentially methylated region (DMR), is imprinted and may show allele-specific 249 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101/2022.03.05.22271944 doi: medRxiv preprint 14 expression. VTRNA2-1 is a metastable epiallele with accumulating evidence that methylation at this 250 region is heritable, modifiable, and associated with disease including risk and progression of 251 cancer(35). 252

We found that, in IgAN patients with downregulated VTRNA2-1, PKR is overactivated, coherently 253 with the role of the VTRNA2-1 that binds to PKR and inhibits its phosphorylation (36). The loss of 254 this natural restrain causes the activation of CREB, a classical cAMP-inducible CRE-binding factor 255 interacting with a region of the IL-6 promoter (that is known as CRE-like sequence), leading to IL-6 256 production (20-24). 257

The discovery of the upregulation of the PKR/CREB/IL-6 in IgAN patients is very suggestive. PKR 259 is normally activated by double-strand bacterial(25,26) and single-strand viral (27,28) RNA and has 260 long been recognized as a key mediator of the innate immunity response to viral infection. Expression 261 of latent PKR is induced by interferon and it is activated upon binding to viral RNA containing duplex 262 regions to undergo autophosphorylation. The data showing that, in IgAN patients, the PKR signalling 263 is already activated due to their epigenetic background could explain why the disease has traditionally 264 been considered as correlated to mucosal infections because of the clinical manifestation of hematuria 265 following upper respiratory tract microbes challenge(37,38). Bacterial and viral RNA may effectively 266 further activate the PKR/CREB/IL-6 pathway leading to an excess of IL-6 production. 267

IgAN patients displayed a significantly higher frequency of EBV infection than did cells of the same 270 phenotype from non-IgAN patients(39). Interestingly, a different study very recently showed that 271 PKR is regulated by EBV RNA(40). 272

This kind of mechanism, driven by the epigenetic silencing of VTRNA2-1, may therefore explain 273 both the high levels of IL-6, and infection involvement in the disease, and recent data showing 274 microbiota involvment in IgAN (9) (41) (42). Our hypothesis is also supported by studies showing 275 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 15 that synthetic double-stranded RNA poly (I:C (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Real Time-PCR was performed in triplicate, and relative expression was calculated using the 2−ΔCt 342 method. 343 344 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. PBMCs of HS and IgAN patients were seeded in 6-well plates at a density of 2 x 10 6 cells/cm 2 and 361 were incubated with specific medium. Xfect Transfection Reagent (Clontech,Takara bio, France) was 362 used to transfect 20 ug of Poly (I:C) (InvivoGen, Europe), a synthetic analogue of dsRNA, in PBMC 363 cells, according to manufacturer's instructions. Imoxin (Chem Cruz) was added to PBMCs at a 364 concentration of 1 µM. After two days of incubation with Poly (I:C) and/or Imoxin the secretion of 365 IL-6 levels by PBMCs were measured in the cell culture supernatants. 366 367

Statistical analyses were performed using the Student's t-test, as appropriate. A p-value < 0.05 was 369 considered significant. Data are expressed as means ± SEM. 370 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis

The Pathophysiology of IgA Nephropathy

Genome-wide scan identifies a copy number variable region at 3p21.1 381 that influences the TLR9 expression levels in IgA nephropathy patients

IgA class switching in APRIL-deficient mice

Discovery of new risk loci for IgA nephropathy implicates genes involved 388 in immunity against intestinal pathogens

The intestine-renal connection in IgA nephropathy

Gluten exacerbates IgA nephropathy in 394 humanized mice through gliadin-CD89 interaction

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 7, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (2020) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 7, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 26 in T-IgAN patients with VTRNA2-1/PKR/CREB activated pathway compared to TP group, even if 556 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 7, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022